Impact of coronary artery disease on clinical outcomes after TAVR: Insights from the BRAVO‐3 randomized trial

Abstract

AbstractObjectiveTo determine the prognostic impact of coronary artery disease (CAD) in patients randomized to bivalirudin or unfractionated heparin (UFH) during transcatheter aortic valve replacement (TAVR).BackgroundCAD is a common comorbidity among patients undergoing TAVR and studies provide conflicting data on its prognostic impact.MethodsThe Bivalirudin on Aortic Valve Intervention Outcomes‐3 (BRAVO‐3) randomized trial compared the use of bivalirudin versus UFH in 802 high‐surgical risk patients undergoing transfemoral TAVR for severe symptomatic aortic stenosis. Patients were stratified according to the presence or absence of history of CAD as well as periprocedural anticoagulation. The coprimary endpoints were net adverse cardiac events (NACE; a composite of all‐cause mortality, myocardial infarction, stroke, or major bleeding) and major Bleeding Academic Research Consortium (BARC) bleeding ≥3b at 30 days postprocedure.ResultsAmong 801 patients, 437 (54.6%) had history of CAD of whom 223 (51.0%) received bivalirudin. There were no significant differences in NACE (adjusted odds ratio [OR]: 1.04; 95% confidence interval [CI]: 0.69–1.58) or BARC ≥ 3b bleeding (adjusted OR: 0.84; 95% CI: 0.51–1.39) in patients with vs without CAD at 30 days. Among CAD patients, periprocedural use of bivalirudin was associated with similar NACE (OR: 0.80; 95% CI: 0.47–1.35) and BARC ≥ 3b bleeding (OR: 0.64; 95% CI: 0.33–1.25) compared with UFH, irrespective of history of CAD (p‐interaction = 0.959 for NACE; p‐interaction = 0.479 for major bleeding).ConclusionCAD was not associated with a higher short‐term risk of NACE or major bleeding after TAVR. Periprocedural anticoagulation with bivalirudin did not show any advantage over UFH in patients with and without CAD.